These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7730497)

  • 1. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics.
    Meltzer HY
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):2S-3S. PubMed ID: 7730497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of the serotonin-dopamine antagonist concept.
    Huttunen M
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):4S-10S. PubMed ID: 7730499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of serotonin in antipsychotic drug action.
    Meltzer HY
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
    Kuroki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
    Remington G; Kapur S
    J Clin Psychiatry; 1999; 60 Suppl 10():15-9. PubMed ID: 10340683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
    Chaki S; Funakoshi T; Yoshikawa R; Okuyama S; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropharmacological profile of an atypical antipsychotic, NRA0562.
    Hirota S; Kawashima N; Chaki S; Okuyama S
    CNS Drug Rev; 2003; 9(4):375-88. PubMed ID: 14647530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Batool F; Hasnat A; Haleem MA; Haleem DJ
    Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of serotonin in the action of atypical antipsychotic drugs.
    Meltzer HY
    Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.